Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy

Thierry M. Muanza, Paul S. Albert, Sharon Smith, Denise Godette, Nancy Sears Crouse, Theresa Cooley-Zgela, Linda Sciuto, Kevin Camphausen, C. Norman Coleman, Cynthia Ménard

Research output: Contribution to journalArticle

Abstract

Purpose: This study strives to compare early measures of bowel toxicity in patients with prostate cancer receiving definitive or adjuvant 3D conformal external beam radiation therapy and concurrent daily endorectal application of amifostine. Methods: Eighteen patients were enrolled in the clinical study with a median follow-up of 12 months. Prescription doses ranged from 66 Gy to 76 Gy with a daily fractionation of 2 Gy. Acute bowel toxicity was measured at baseline, at Weeks 5 and 7 of radiotherapy, and at 1 and 3 months after the completion of therapy. Measures of acute bowel toxicity included the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria, Expanded Prostate Cancer Index Composite (EPIC) self-assessment questionnaires, and proctoscopic examinations. Results: The mean EPIC bowel scores changed significantly through the course of therapy and follow-up (p <0.0001), with a progressive decrease in scores at Weeks 5 and 7 of treatment, a partial recovery at 3 months, and a correlation to the gold standard RTOG grade (p = 0.004). Proctoscopic toxicity scores were low, did not vary over time, and did not correlate with either EPIC or RTOG scores. Conclusion: The EPIC questionnaire measurements are most sensitive to changes in acute bowel toxicity through a course of radiotherapy and correlate with RTOG acute toxicity scores. Endoscopic examination of the rectal mucosa at the end and immediate follow-up of a course of therapy does not seem to be informative or reproducible between observers in the acute setting.

Original languageEnglish (US)
Pages (from-to)1316-1321
Number of pages6
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume62
Issue number5
DOIs
StatePublished - Aug 1 2005
Externally publishedYes

Fingerprint

toxicity
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Radiation Oncology
therapy
composite materials
examination
Amifostine
scoring
Therapeutics
fractionation
Prescriptions
grade
Mucous Membrane
recovery
Radiation
Morbidity
dosage

Keywords

  • Bowel toxicity
  • Endoscopy
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. / Muanza, Thierry M.; Albert, Paul S.; Smith, Sharon; Godette, Denise; Crouse, Nancy Sears; Cooley-Zgela, Theresa; Sciuto, Linda; Camphausen, Kevin; Coleman, C. Norman; Ménard, Cynthia.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 62, No. 5, 01.08.2005, p. 1316-1321.

Research output: Contribution to journalArticle

Muanza, TM, Albert, PS, Smith, S, Godette, D, Crouse, NS, Cooley-Zgela, T, Sciuto, L, Camphausen, K, Coleman, CN & Ménard, C 2005, 'Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy', International Journal of Radiation Oncology, Biology, Physics, vol. 62, no. 5, pp. 1316-1321. https://doi.org/10.1016/j.ijrobp.2004.12.083
Muanza, Thierry M. ; Albert, Paul S. ; Smith, Sharon ; Godette, Denise ; Crouse, Nancy Sears ; Cooley-Zgela, Theresa ; Sciuto, Linda ; Camphausen, Kevin ; Coleman, C. Norman ; Ménard, Cynthia. / Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. In: International Journal of Radiation Oncology, Biology, Physics. 2005 ; Vol. 62, No. 5. pp. 1316-1321.
@article{cef661d3ad8947f6b2aa028acc727f13,
title = "Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy",
abstract = "Purpose: This study strives to compare early measures of bowel toxicity in patients with prostate cancer receiving definitive or adjuvant 3D conformal external beam radiation therapy and concurrent daily endorectal application of amifostine. Methods: Eighteen patients were enrolled in the clinical study with a median follow-up of 12 months. Prescription doses ranged from 66 Gy to 76 Gy with a daily fractionation of 2 Gy. Acute bowel toxicity was measured at baseline, at Weeks 5 and 7 of radiotherapy, and at 1 and 3 months after the completion of therapy. Measures of acute bowel toxicity included the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria, Expanded Prostate Cancer Index Composite (EPIC) self-assessment questionnaires, and proctoscopic examinations. Results: The mean EPIC bowel scores changed significantly through the course of therapy and follow-up (p <0.0001), with a progressive decrease in scores at Weeks 5 and 7 of treatment, a partial recovery at 3 months, and a correlation to the gold standard RTOG grade (p = 0.004). Proctoscopic toxicity scores were low, did not vary over time, and did not correlate with either EPIC or RTOG scores. Conclusion: The EPIC questionnaire measurements are most sensitive to changes in acute bowel toxicity through a course of radiotherapy and correlate with RTOG acute toxicity scores. Endoscopic examination of the rectal mucosa at the end and immediate follow-up of a course of therapy does not seem to be informative or reproducible between observers in the acute setting.",
keywords = "Bowel toxicity, Endoscopy, Prostate cancer, Radiation",
author = "Muanza, {Thierry M.} and Albert, {Paul S.} and Sharon Smith and Denise Godette and Crouse, {Nancy Sears} and Theresa Cooley-Zgela and Linda Sciuto and Kevin Camphausen and Coleman, {C. Norman} and Cynthia M{\'e}nard",
year = "2005",
month = "8",
day = "1",
doi = "10.1016/j.ijrobp.2004.12.083",
language = "English (US)",
volume = "62",
pages = "1316--1321",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy

AU - Muanza, Thierry M.

AU - Albert, Paul S.

AU - Smith, Sharon

AU - Godette, Denise

AU - Crouse, Nancy Sears

AU - Cooley-Zgela, Theresa

AU - Sciuto, Linda

AU - Camphausen, Kevin

AU - Coleman, C. Norman

AU - Ménard, Cynthia

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Purpose: This study strives to compare early measures of bowel toxicity in patients with prostate cancer receiving definitive or adjuvant 3D conformal external beam radiation therapy and concurrent daily endorectal application of amifostine. Methods: Eighteen patients were enrolled in the clinical study with a median follow-up of 12 months. Prescription doses ranged from 66 Gy to 76 Gy with a daily fractionation of 2 Gy. Acute bowel toxicity was measured at baseline, at Weeks 5 and 7 of radiotherapy, and at 1 and 3 months after the completion of therapy. Measures of acute bowel toxicity included the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria, Expanded Prostate Cancer Index Composite (EPIC) self-assessment questionnaires, and proctoscopic examinations. Results: The mean EPIC bowel scores changed significantly through the course of therapy and follow-up (p <0.0001), with a progressive decrease in scores at Weeks 5 and 7 of treatment, a partial recovery at 3 months, and a correlation to the gold standard RTOG grade (p = 0.004). Proctoscopic toxicity scores were low, did not vary over time, and did not correlate with either EPIC or RTOG scores. Conclusion: The EPIC questionnaire measurements are most sensitive to changes in acute bowel toxicity through a course of radiotherapy and correlate with RTOG acute toxicity scores. Endoscopic examination of the rectal mucosa at the end and immediate follow-up of a course of therapy does not seem to be informative or reproducible between observers in the acute setting.

AB - Purpose: This study strives to compare early measures of bowel toxicity in patients with prostate cancer receiving definitive or adjuvant 3D conformal external beam radiation therapy and concurrent daily endorectal application of amifostine. Methods: Eighteen patients were enrolled in the clinical study with a median follow-up of 12 months. Prescription doses ranged from 66 Gy to 76 Gy with a daily fractionation of 2 Gy. Acute bowel toxicity was measured at baseline, at Weeks 5 and 7 of radiotherapy, and at 1 and 3 months after the completion of therapy. Measures of acute bowel toxicity included the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria, Expanded Prostate Cancer Index Composite (EPIC) self-assessment questionnaires, and proctoscopic examinations. Results: The mean EPIC bowel scores changed significantly through the course of therapy and follow-up (p <0.0001), with a progressive decrease in scores at Weeks 5 and 7 of treatment, a partial recovery at 3 months, and a correlation to the gold standard RTOG grade (p = 0.004). Proctoscopic toxicity scores were low, did not vary over time, and did not correlate with either EPIC or RTOG scores. Conclusion: The EPIC questionnaire measurements are most sensitive to changes in acute bowel toxicity through a course of radiotherapy and correlate with RTOG acute toxicity scores. Endoscopic examination of the rectal mucosa at the end and immediate follow-up of a course of therapy does not seem to be informative or reproducible between observers in the acute setting.

KW - Bowel toxicity

KW - Endoscopy

KW - Prostate cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=22144480041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144480041&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2004.12.083

DO - 10.1016/j.ijrobp.2004.12.083

M3 - Article

C2 - 16029787

AN - SCOPUS:22144480041

VL - 62

SP - 1316

EP - 1321

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -